1. Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer
- Author
-
Tacconi, C, Ungaro, Francesco, Correale, C, Arena, Vincenzo, Massimino, L, Detmar, M, Spinelli, Adriano, Carvello, M, Mazzone, Marinella, Oliveira, Ai, Rubbino, F, Garlatti, V, Spano, S, Lugli, E, Colombo, F, Malesci, A, Peyrin-Biroulet, L, Vetrano, S, Danese, Silvio, D'Alessio, S, Ungaro, F, Arena, V (ORCID:0000-0002-7562-223X), Spinelli, A, Mazzone, M, Danese, S, Tacconi, C, Ungaro, Francesco, Correale, C, Arena, Vincenzo, Massimino, L, Detmar, M, Spinelli, Adriano, Carvello, M, Mazzone, Marinella, Oliveira, Ai, Rubbino, F, Garlatti, V, Spano, S, Lugli, E, Colombo, F, Malesci, A, Peyrin-Biroulet, L, Vetrano, S, Danese, Silvio, D'Alessio, S, Ungaro, F, Arena, V (ORCID:0000-0002-7562-223X), Spinelli, A, Mazzone, M, and Danese, S
- Abstract
Colorectal cancer is a major cause of cancer-related death in Western countries and is associated with increased numbers of lymphatic vessels (LV) and tumor-associated macrophages (TAM). The VEGFC/VEGFR3 pathway is regarded as the principal inducer of lymphangiogenesis and it contributes to metastases; however, no data are available regarding its role during primary colorectal cancer development. We found that both VEGFC and VEGFR3 were upregulated in human non-metastatic colorectal cancer, with VEGFR3 expressed on both LVs and TAMs. With the use of three different preclinical models of colorectal cancer, we also discovered that the VEGFC/VEGFR3 axis can shape both lymphatic endothelial cells and TAMs to synergistically inhibit antitumor immunity and promote primary colorectal cancer growth. Therefore, VEGFR3-directed therapy could be envisioned for the treatment of nonmetastatic colorectal cancer.Significance: The prolymphangiogenic factor VEGFC is abundant in colorectal cancer and activates VEGFR3 present on cancer-associated macrophages and lymphatic vessels; activation of VEGFR3 signaling fosters cancer immune escape, resulting in enhanced tumor growth.
- Published
- 2019